secwatch / observer
8-K filed June 18, 2026, 5:00 PM ET ticker CLDI CIK 0001855485
other material confidence high sentiment neutral materiality 0.60

Stockholders approve reverse stock split (1:2 to 1:16) and equity plan increase to 1.95M shares

Calidi Biotherapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Calidi Biotherapeutics, Inc. shareholders approved 2023 Plan Amendment at the 2026-06-12 meeting.

Proposal
equity plan
Outcome
passed
Meeting
2026-06-12
Exact text from the filing
Stockholders approved an amendment to the Company’s 2023 Equity Incentive Plan (the “2023 Plan”), to increase the aggregate number of shares of common stock authorized for grant under the 2023 Plan from 282,815 to 1,950,000.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Calidi Biotherapeutics, Inc. shareholders approved Reverse Stock Split at the 2026-06-12 meeting.

Proposal
reverse split
Outcome
passed
Meeting
2026-06-12
Exact text from the filing
Stockholders approved an amendment to the Company’s Second Amended and Restated Certificate of Incorporation, as amended, to, at the discretion of the Board of Directors, effect a reverse stock split with respect to the Company’s shares of issued and outstanding Common Stock, which consists of Voting Common Stock and Non-Voting Common Stock, at a ratio between 1-for-2 and 1-for-16 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board and included in a public announcement.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Calidi Biotherapeutics, Inc. shareholders approved Ratification of the appointment of Auditor at the 2026-06-12 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-12
Exact text from the filing
Stockholders approved and ratified the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm to audit the consolidated financial statements of the Company for the fiscal year ending December 31, 2026.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Calidi Biotherapeutics, Inc. shareholders approved Election of Class III Director Nominee at the 2026-06-12 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-06-12
Exact text from the filing
The stockholders elected Scott Leftwich as Class III Director of the Company by a plurality of the votes cast, and without contest, to serve a three-year term until the 2029 Annual Meeting of Stockholders or until his successor has been duly elected.
View on SEC.gov

1183 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Calidi Biotherapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001493152-26-029374
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.